BENZENO SHARON 4

What Happened

• Sharon Benzeno, Chief Commercial Officer (Immune Medicine) at Adaptive Biotechnologies, reported a sale of 63,103 shares on 2026-03-11 at $13.17 per share, totaling about $831,067. The Form 4 was filed on 2026-03-13.
• The filing indicates this was a sell-to-cover transaction to satisfy tax withholding on vested RSUs, not a discretionary open-market trade.

Key Details

• Transaction date: 2026-03-11; reported on Form 4 filed 2026-03-13 (timely).
• Type: Sale (reported as open-market or private sale); 63,103 shares at $13.17 each; proceeds ≈ $831,067.
• Footnote: Sale required to cover tax withholding for RSU vesting (issuer-mandated "sell to cover"); not a discretionary trade by the reporting person (Footnote F1).
• Shares owned after transaction: not specified in the provided filing.
• Accession (for reference): 0001780854-26-000004.

Context

• Sell-to-cover transactions occur when an insider’s restricted stock units vest and the company requires withholding taxes to be satisfied by selling a portion of the shares. These are routine and generally do not signal a change in the insider’s view of the company.
• For retail investors, purchases typically carry more informational weight than mandated sell-to-cover sales; treat this filing as a tax-related liquidity event rather than an investment decision.